OFM
Omega Fund Management Portfolio holdings
AUM
$154M
This Quarter Return
-19.51%
1 Year Return
-32.78%
3 Year Return
+82.35%
5 Year Return
+29.08%
10 Year Return
+90.46%
AUM
$178M
AUM Growth
+$178M
(-10%)
Cap. Flow
+$18.5M
Cap. Flow
% of AUM
10.43%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
4
Increased
–
Reduced
2
Closed
1
Top Buys
| 1 |
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
|
$10.9M |
| 2 |
ESSA Pharma
EPIX
|
$6.88M |
| 3 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$4.55M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$1.26M |
Top Sells
| 1 |
FibroGen
FGEN
|
$2.19M |
| 2 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
$1.85M |
| 3 |
AKAO
Achaogen, Inc.
AKAO
|
$1M |
Sector Composition
| 1 | Healthcare | 68.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
| $54.1M | 30.46% | 1,329,512 -45,488 | -3% | -$1.85M |
|
|
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $40.6M | 22.88% | 2,138,872 | – | – |
|
|
EGLT
3
DELISTED
Egalet Corporation
EGLT
| $34.9M | 19.63% | 2,645,558 | – | – |
|
|
4
FibroGen
FGEN
$47.8M
| $19.1M | 10.76% | 872,175 -100,000 | -10% | -$2.19M |
|
|
NBRV
5
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $10.9M | 6.13% | +1,145,890 | New | +$10.9M |
|
|
6
ESSA Pharma
EPIX
$11.4M
| $6.88M | 3.88% | +1,090,909 | New | +$6.88M |
|
|
PVLA
7
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $4.55M | 2.56% | +2,483,949 | New | +$4.55M |
|
8
Protara Therapeutics
TARA
$120M
| $3.48M | 1.96% | 250,000 | – | – |
|
|
DRNA
9
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $1.84M | 1.03% | 223,457 | – | – |
|
|
CBAY
10
DELISTED
Cymabay Therapeutics
CBAY
| $1.26M | 0.71% | +650,000 | New | +$1.26M |
|
|
AKAO
11
DELISTED
Achaogen, Inc.
AKAO
| – | – | -166,450 | Closed | -$1M |
|